PDF下载 ( 1965 KB)
HBV reactivation in patients with IgG4-related sclerosing cholangitis after liver transplantation: A case report
-
摘要:
<正>原位肝移植技术的日渐成熟已成为治疗各种终末期肝病的有效手段之一,免疫抑制剂的应用大大减少了术后急慢性排斥反应发生率,显著提高了肝移植受者的长期存活率,但受者也需要承受长期服用免疫抑制剂所带来的不良反应,如感染、肾功能不全、原发病复发等副作用,其中HBV再激活相关性急性肝衰竭日益得到关注,成为影响肝移植远期疗效的重要因素之一。本文介绍Ig G4相关硬化性胆管炎患者肝移植术后使用免疫抑制剂致HBV再激活1例,现报道如下。
-
Key words:
- cholangitis, sclerosing /
- immunoglobulin G /
- liver transplantation /
- hepatitis B virus /
- case reports
-
[1]LOOMBA R, LING TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies:Current concepts, management strategies, and future directions[J].Gastroenterology, 2017, 152 (6) :1297-1309. [2]COLUCCIO C, BEGINI P, MARZANO A, et al. Hepatitis B in patients with hematological diseases:An update[J]. World J Hepatol, 2017, 9 (25) :1043. [3]CHOLONGITAS E, HAIDICH AB. Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy:A systematic review[J]. Ann Gastroenterol, 2018, 31 (4) :480-490. [4]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J]. J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960. [5]PISATURO M, DI CAPRIO G, CALF, et al. Management of HBV reactivation in non-oncological patients[J]. Expert Rev Anti Infect Ther, 2018, 16 (8) :611-624. [6]AYGEN B, DEMIR AM, GMM, et al. Immunosuppressive therapy and the risk of hepatitis B reactivation:Consensus report[J]. Turk J Gastroenterol, 2018, 29 (3) :259-269. [7]BESSONE F, DIRCHWORLF M. Management of hepatitis B reactivation in immunosuppressed patients:An update on current recommendations[J]. World J Hepatol, 2016, 8 (8) :385-394. [8]DOH HK, SEOK BK. Hepatic failure by spontaneous reactivation of hepatitis B virus without a trigger factor in a patient with antiHBs[J]. Case Rep Gastroenterol, 2018, 12 (2) :286-291. [9]DONG KH, FANG YN, KUI YW, et al. Management and prevention of HBV reactivation in the context of immunosuppression[J].J Clin Hepatol, 2018, 34 (10) :2213-2216. (in Chinese) 董凯惠, 方伊娜, 蒉乙文, 等.免疫抑制背景下HBV再激活的管理和预防[J].临床肝胆病杂志, 2018, 34 (10) :2213-2216. [10]YU YC, HOU JL. The highlights of EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J]. J Clin Hepatol, 2017, 33 (6) :1017-1032. (in Chinese) 于乐成, 侯金林. 2017年欧洲肝病学会临床实践指南:HBV感染的管理 (精粹) [J].临床肝胆病杂志, 2017, 33 (6) :1017-1032. -
本文二维码
计量
- 文章访问数: 1019
- HTML全文浏览量: 14
- PDF下载量: 256
- 被引次数: 0
下载:
